Tradestie Institutional Equity Comparison Engine

MAIA vs SRZN โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

SRZN Overall Edge

SRZN Captures Institutional Edge (3โ€“1 Pillars ยท 5โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Surrozen, Inc. Common (SRZN) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while MAIA counters with relative strength in Valuation. Fundamentally, MAIA trades at 1.2x Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus SRZN at N/M Forward P/E and -485.4% operating margin (+408.6% YoY). In options structure, MAIA sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against SRZN sits in CONSOLIDATION (13th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner MAIA
MAIA 1.2x vs SRZN N/M Fwd P/E
Growth & Margin Winner SRZN
Op Margin 0.0% vs -485.4% ยท YoY +0.0% vs +408.6%
Momentum & Technical Winner SRZN
1Y +20.6% vs +110.8% ยท 52W Pos 10% vs 63%
Options & Structure Winner SRZN
UNCLASSIFIED (N/A IV) vs CONSOLIDATION (13th %ile IV)
MAIA NYSE American
MAIA Biotechnology, Inc.
Pharmaceutical Preparations
$1.11
-2.63% 1D
Market Cap $68.5M
1M Return -1.77%
1Y Return +20.65%
Forward P/E 1.2x
Unified AI Score
37.6 / 100 SELL
Tech 40.0 Fund 38.0 Flow 50.0 Mom 44.0
SRZN NASDAQ
Surrozen, Inc. Common
Biological Products, (No Disgnostic Substances)
$28.46
-7.21% 1D
Market Cap $642.7M
1M Return +10.52%
1Y Return +110.81%
Forward P/E N/M
Unified AI Score
36.0 / 100 SELL
Tech 15.0 Fund 42.0 Flow 65.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: MAIA +20.65% SRZN +110.81% Spread: +90.16 pp (SRZN Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
MAIA TTM Op. Margin: 0.0% SRZN TTM Op. Margin: -485.4%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MAIA vs SRZN. Trailing 12-month operating profitability (MAIA 0.0% vs SRZN -485.4%) and valuation multiples (MAIA 1.2x vs SRZN N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: MAIA (4) vs SRZN (5)
Institutional Metric MAIA SRZN Criterion Row Winner
Market Capitalization Scale $68.5M $642.7M Larger Scale SRZN
Trailing P/E Ratio Valuation 1.2x N/M Lower Multiple MAIA
Forward P/E Ratio Valuation 1.2x N/M Lower Multiple MAIA
Revenue Growth (YoY) Growth +0.0% +408.6% Higher Growth SRZN
Operating Margin (TTM) Profitability 0.0% -485.4% Higher Margin MAIA
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -341.5% -62.8% Higher ROE SRZN
52-Week Range Position Momentum 10% ($1โ€“$3) 63% ($13โ€“$38) Stronger Trend SRZN
Beta / 30D Volatility Risk Regime 1.65ฮฒ ยท 108% Vol 1.29ฮฒ ยท 73% Vol Lower Realized Risk SRZN
Unified Institutional Score Composite Signal 37.6 / 100 (SELL) 36.0 / 100 (SELL) Higher Composite MAIA

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full MAIA vs SRZN Buy Guide
MAIA UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live MAIA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
SRZN CONSOLIDATION
41d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 13th %ile
IV Regime Compressed (<25th %ile)
Live SRZN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither MAIA nor SRZN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.